You need AI to improve productivity. But AI does not take out responsibilities especially in regulated industries. In drug discovery and big pharmaceuticals, AI will improve workflows, but AI outputs must still be evaluated by humans.
Redouble AI (redouble.ai) scales human-in-the-loop for AI workflows in regulated industries. Simply, it improves the efficiency of human elements in reviewing the outputs of AI systems: “Instead of having to rely on slow and expensive human reviewers, Redouble’s clients save 80% of staff costs and significantly improve the accuracy and quality of their outputs by integrating our tool into their workflows.”
The team includes a medical doctor and an Oxford PhD, ex-AI drug discovery startup founder, ex-CEO of a small pharma and ex-Novartis engineer, providing the star nexus to execute the complex mission.
Register for Tekedia Mini-MBA edition 19 (Feb 9 – May 2, 2026): big discounts for early bird.
Tekedia AI in Business Masterclass opens registrations.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab: From Technical Design to Deployment (next edition begins Jan 24 2026).
The foundation stack of their product will work for securities and the broad capital market even as they’re starting in drug discovery and pharma. Tekedia Capital (capital.tekedia.com) welcomes Redouble AI to our community, and asks companies in this industry to schedule demos with the company. They’re growing rapidly because Redouble AI is bringing order in the fledgling AI sector in pharma and making drugs.
---
Connect via my
LinkedIn |
Facebook |
X |
TikTok |
Instagram |
YouTube